Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-20

Clinical Trial Update: A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) [Phase 4]

View source ↗

Summary

A Phase 4 trial of rofecoxib in familial adenomatous polyposis (Adenomatous Polyposis Coli) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rofecoxib (rofecoxib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Adenomatous Polyposis Coli | Phase 4 | Status: TERMINATED